Current management of lupus nephritis: Popular misconceptions

Lupus

Volumn 16, Issue 3, 2007, Pages 217-220

  Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Cyclophosphamide; Kidney disease; Kidney failure; Lupus nephritis; Mycophenolate mofetil; Treatment

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL CARE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; REMISSION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MYCOPHENOLIC ACID;

EID: 33947726021     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306075614     Document Type: Conference Paper

References (17)

1. Cross J, Jayne D. Kidney International Society Abstracts 2001. Autumn Meeting of the UK Renal Association (Abstract 56), 2001.
2. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208.
3. Illei GG, Austin III HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
4. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006; 8: R182.
5. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin in Rheumatol 2001; 13: 345-351.
6. Cook RJ, Gladman DD, Pericak D, Urowitz MB. Prediction of short-term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol 2000; 27: 1892-1895.
7. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904-914.
8. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-3940.
9. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
10. Cross J, Dwomoa A, Andrews P et al. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 2005; 100: c92-100.
11. Tumlin S. ASN 2004; J Am Soc of Neph. annual meeting abstract FC046.
12. Ding L, Zhao M, Zou W, Liu Y, Wang H. Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus 2004; 13: 113-118.
13. Schnitzler MA, Craig KE, Hardinger KE, Lowell JA, Brennan DC. Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. Nephrol Dial Transplant 2003; 18: 1197-1200.
14. Shimuzi H, Takahashi M, Takeda S-I et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004; 77: 1661-1667.
15. Moroni G, Quaglini A, Maccario M, Banfi G, Ponticelli C. 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-2053.
16. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
17. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003; 82: 299-308.